同: dihydrofolate, ジヒドロ葉酸

WordNet

the 4th letter of the Roman alphabet (同)d

PrepTutorEJDIC

deuteriumの化学記号

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/10/31 04:53:28」(JST)

wiki en

Design History File is a compilation of documentation that describes the design history of a finished medical device. The design history file, or DHF, is part of regulation introduced in 1990 when the U.S. Congress passed the Safe Medical Devices Act, which established new standards for medical devices that can cause or contribute to the death, serious illness, or injury of a patient.^[1] Prior to this legislation, U.S. Food and Drug Administration (FDA) auditors were limited to examining the production and quality control records of the device.

Requirements

The regulation requires of medical devices manufacturers of Class II and Class III devices to implement design controls. These design controls consist of a development and control plan used to manage the development of a new product, and a design history file where these activities are documented. These controls are specifically intended to manage a medical device company's new product development activities. Research and development processes aimed at developing new underlying technologies are not subject to these regulations. The requirements for a DHF are documented in FDA Regulation CFR 21 820.^[1]

Design controls

Each manufacturer of either a class II or class III medical device (as well as a select group of class I devices) needs to establish and document procedures on the design and design requirements. These design controls include:^[2]

Design input - Design inputs are typically the initial requirements that describe the medical device to be produced.

Design output - Design outputs are the results of the design and engineering efforts. These are normally the final specifications for the device. Including the manufacturing process and the in-coming, in-process and finished device inspection, measurement or test methods and criteria. The outputs are normally documented in models, drawings, engineering analysis and other documents. The output needs to be directly traceable to the input requirements. Design verification and validation should demonstrate that the final output specifications conform to the input requirements and meet user needs and intended uses.

Design review - The design review is a formal review of the medical device design by representatives of each design function participating in the design efforts as well as other interested parties (e.g. marketing, sales, manufacturing engineering, etc.). The design review must be documented in the DHF and include review date, participants, design version/revision reviewed and review results.

Design verification - Design verification is the process that confirms that the design output conforms to the design input. Design verification should demonstrate that the specifications are the correct specifications for the design. Design verification must be documented in the DHF and include the verification date, participants, design version/revision verified, verification method and verification results.

Design validation - Design validation is the process in which the device design is validated using initial/low volume production processes. The purpose for the design validation is to confirm that the design functions according to design inputs when produced using normal production processes rather than prototype processes. The design validation must be documented in the DHF.

Design transfer - Design transfer is the process in which the device design is translated into production, distribution, and installation specifications.

Design changes - Design changes is the process in which the design changes are identified and documented. Also known as engineering change or enterprise change.

Design history file - The DHF is a formal document that is prepared for each medical device. The DHF can be either a collection of the actual documents generated in the product development (PD) process or an index of documents and their storage location.

References

^ ^a ^b Harnack, Gordon (1999). Mastering and Managing the FDA Maze: Medical Device Overview. American Society for Qualit. ISBN 978-0-87389-455-5.
^ Device Inspections Guide. Washington Business Information. p. 52657. ISBN 978-1-932074-10-9.

External links

CFR Title 21 Database

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 拡張期心不全の治療および予後 treatment and prognosis of diastolic heart failure
2. 拡張期心不全の病態生理 pathophysiology of diastolic heart failure
3. 拡張期心不全の臨床症状および診断 clinical manifestations and diagnosis of diastolic heart failure
4. デング熱ウイルス感染症の予防および治療 prevention and treatment of dengue virus infection
5. デング熱ウイルス感染症の病因 pathogenesis of dengue virus infection

English Journal

Dengue Hemorrhagic Fever at 60 Years: Early Evolution of Concepts of Causation and Treatment.

Halstead SB1, Cohen SN2.
Microbiology and molecular biology reviews : MMBR.Microbiol Mol Biol Rev.2015 Sep;79(3):281-291.
During the decade of the 1960s, the epidemiology of a new dengue disease, dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS), was described by collaborative research performed by Thai scientists from many institutions and by workers at the U.S. Army's SEATO Medical Research Laboratory in B
PMID 26085471

Association of combinations of interleukin-10 and pro-inflammatory cytokine gene polymorphisms with dengue hemorrhagic fever.

Alagarasu K1, Bachal RV2, Tillu H2, Mulay AP2, Kakade MB2, Shah PS2, Cecilia D2.
Cytokine.Cytokine.2015 Jul;74(1):130-6. doi: 10.1016/j.cyto.2015.03.021. Epub 2015 Apr 16.
Pro-inflammatory and anti-inflammatory cytokines have been shown to play an important role in dengue disease pathogenesis. In the present study, to find out whether single nucleotide polymorphisms (SNPs) in the pro-inflammatory and anti-inflammatory cytokine genes are associated with dengue disease
PMID 25890879

Proteomic analysis of immunogenic proteins from salivary glands of Aedes aegypti.

Oktarianti R1, Senjarini K2, Hayano T3, Fatchiyah F4, Aulanni'am5.
Journal of infection and public health.J Infect Public Health.2015 Jun 5. pii: S1876-0341(15)00089-1. doi: 10.1016/j.jiph.2015.04.022. [Epub ahead of print]
Humans develop anti-salivary proteins after arthropod bites or exposure to insect salivary proteins. This reaction indicates that vector bites have a positive effect on the host immune response, which can be used as epidemiological markers of exposure to the vector. Our previous study identified two
PMID 26054892